A cleaner RAS bet with real IP danger
- Erasca has no approved products and no product revenue yet.
- The company has stopped naporafenib and other legacy programs to focus on ERAS-0015 and ERAS-4001.
- ERAS-0015 showed positive early Phase 1 data in April 2026, which moved expansion and combination testing forward.
- Cash is expected to fund operations into the second half of 2028.
- Revolution Medicines has raised a serious patent and trade secret claim against ERAS-0015.
Cleaner story, sharper risk
Erasca is now a much simpler company. It stopped development of naporafenib and formally ended several older license deals. That leaves a focused RAS franchise, led by ERAS-0015 and ERAS-4001.
The bull case is that this focus is starting to pay off. ERAS-0015 reported positive preliminary Phase 1 dose escalation data in April 2026. The company then began monotherapy expansion and combination dose escalation cohorts ahead of prior guidance. Collaborations with Tango Therapeutics and Merck for ERAS-0015 combinations also give outside support to the program.
The bear case is that the company is now highly concentrated. If ERAS-0015 or ERAS-4001 fails in early trials, there is little else near the clinic to carry the story. The biggest added concern is legal: Revolution Medicines says ERAS-0015 may infringe its patent and use misappropriated trade secrets.
The next major watch points are the ERAS-4001 BOREALIS-1 Phase 1 monotherapy readout in the second half of 2026, ERAS-0015 expansion and combination data in the first half of 2027, and any update in the Revolution Medicines dispute.
Drug trials before revenue
Erasca does not sell a drug today. It spends cash to license or discover cancer drug candidates, run clinical trials, and try to create enough data for regulators, partners, or future buyers to care.
The model can create large value if a drug works in a hard cancer target. It can also fail fast. A weak safety result, a lack of tumor response, or a trial delay can erase much of the expected value because there is no commercial business underneath.
Erasca also depends on third parties for manufacturing. That lowers the need to build factories, but it adds supply, quality, and timing risk. New tariffs, export controls, or supply chain problems could slow trials or raise costs.
What is left in the pipeline
ERAS-0015
ERAS-0015 is a pan-RAS molecular glue in the AURORAS-1 Phase 1 trial. It is the lead asset after positive preliminary dose escalation data, but it is also the target of the Revolution Medicines IP claim.
ERAS-4001
ERAS-4001 is a pan-KRAS inhibitor in the BOREALIS-1 Phase 1 trial. Its first monotherapy data readout is expected in the second half of 2026.
ERAS-12
ERAS-12 is a discovery-stage EGFR D2 and D3 biparatopic antibody. It is much earlier than the clinical programs, so it is not the main driver yet.
Legacy programs
Naporafenib, ERAS-007, and ERAS-601 have been terminated or stopped. These programs now matter mostly because their exit shows how sharply Erasca has narrowed its focus.
One research segment
Erasca reports one operating segment: research and development of precision oncology therapeutics. The mix reflects the latest company context through the 2026 Q1 filing, and there is no product revenue to split.
What could break the thesis
ERAS-0015 IP block
High impact · Medium oddsRevolution Medicines sent a legal demand in April 2026. It says ERAS-0015 is substantially equivalent to claims in its patent and involves alleged trade secret misuse. An injunction, forced license, or costly settlement could damage the lead program.
Early clinical failure
High impact · Medium oddsERAS-0015 and ERAS-4001 are still early-stage cancer drugs. Early responses may not repeat in larger cohorts, and side effects can appear as more patients receive the drug. A poor readout would matter more now because the pipeline has been narrowed.
Cash burn and dilution
Medium impact · Medium oddsErasca says cash should fund operations into the second half of 2028. That is useful breathing room, but oncology trials are expensive. If trials expand, legal costs rise, or the stock price weakens, the company may need to raise capital on worse terms.
Partner and supplier dependence
Medium impact · Medium oddsErasca relies on in-licensed assets and third-party manufacturing. License disputes, supply delays, quality failures, or trade restrictions could slow clinical work. Tariffs and import or export limits are a stated risk for development costs and timing.
In one breath
Does Erasca have any approved drugs?
No. Erasca is still a clinical-stage company, so it has no approved products and no product revenue.
What is Erasca mainly betting on now?
The main bet is the RAS franchise, especially ERAS-0015 and ERAS-4001. The company stopped naporafenib and other older programs to focus resources there.
Why does the Revolution Medicines dispute matter?
It targets ERAS-0015, the lead program. If Revolution Medicines wins an injunction or forces a painful license deal, Erasca's main asset could be delayed or weakened.
When are the next important ERAS catalysts?
ERAS-4001 Phase 1 monotherapy data are expected in the second half of 2026. ERAS-0015 expansion and combination data are expected in the first half of 2027.